NANOLOGICA AB - September 17, 2021
- Press releases, Regulatory press releases
Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company's resources on the continued development of the inhalation platform NLAB Spiro®.
The closure of the project is a result of the company's strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001 have changed. As the project is closed, internal resources are transferred to inhalation projects based on the NLAB Spiro® platform. Nanologica believes that the platform has great potential to solve several of the challenges that exist for inhaled medicines.
'Due to the pandemic-related obstacles that have delayed the start of the planned study with NIC-001, we have instead been able to put a lot of resources and focus on our inhalation platform. The technological progress we have made, in combination with the interest we have seen from the market, makes it a natural step for us to refine our strategy within Drug Development to focus on inhalation and respiratory diseases', Andreas Bhagwani, CEO Nanologica, comments.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface characteristics of silica particles. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the betterment of mankind. In Drug Development, the company is committed to leverage its technology platform to solve medical problems in order to provide new treatments for patients with severe lung diseases. In Chromatography, the aim is to make insulin available to more patients in need by reducing the production cost for manufacturers. Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica's stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
About NLAB Spiro®
NLAB Spiro® is Nanologica's technology platform for inhalation. The platform is constituted of biologically degradable nanoporous silica particles that can be loaded with APIs inside the pores of the particles. The particles are spherical, non-aggregating and appears as a free-flowing powder. The aerodynamical properties are tailored for inhalation and the particle size ranges between 2 µm and 5 µm, which means they can reach a desired part of the lung - the smaller the particle, the deeper into the lung it can reach. Once reaching the lung, the API is released giving a treatment effect locally. NLAB Spiro® can improve solubility and/or the bioavailability of an API, protect an API from degradation, provide a controlled release profile, and enable local treatment with lowered systemic effects, which creates new treatment options for lung diseases.
This information is such that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on September 17, 2021.
2021-09-17 Nanologica Closes NIC-001Attachments
- Original document
- Permalink
Disclaimer
Nanologica AB published this content on 17 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2021 09:21:03 UTC.
